Cold Therapy for Hands & Feet
Cancer treatment can come with challenging side effects that may impact comfort and quality of life. Through the Mission Cancer Foundation’s Cold Therapy Support Program, eligible patients may receive cold therapy gloves and socks to use during treatment.
Cold therapy may help reduce the severity of certain treatment-related side effects and provide additional comfort throughout the treatment journey. If you are interested in learning whether cold therapy may be beneficial for you, please speak with your care team.
Program availability is dependent on funding and inventory.
IS Cold therapy Right for you?
If you have questions regarding cold therapy (Suzzipads) please reach out to your Care Team.
FAQs:
Cold Therapy uses cold temperatures to reduce side effects from certain chemotherapy treatments.
Cold therapy works by blocking chemotherapy from affecting specific areas of the body.
- Nail Damage
- Numbness
- Tingling
- Burning
Patients receiving taxane-based chemotherapy may be eligible for this program.
(ONLY use cold therapy if instructed by your care team)
The Mission Cancer Foundation currently recommends SuzziPad cold therapy gloves and sock.
SuzziPad products can be purchased directly through the manufacturer's website and through Amazon. Patients should speak with their care team before purchasing to determine whether cold therapy is appropriate for their treatment plan.
If cost is preventing you from accessing cold therapy products, the Mission Cancer Foundation may be able to provide SuzziPad gloves and socks to eligible patients through our Cold Therapy Support Program. Please speak with your care team at Mission Cancer + Blood to determine whether you qualify. If you qualify, your care team will contact us directly.
support our Cold Therapy Program
Help provide cold therapy gloves and socks to patients undergoing cancer treatment. Your donation helps ensure eligible patients can access resources that may reduce treatment-related side effects and improve comfort during care.
